NICE rejects lapatinib for advanced breast cancer despite GSK's patient access scheme

摘要

Routine treatment with lapatinib(Tyverb),in combination with capecitabine,in advanced or metastatic breast cancer is not a cost effective use of NHS resources,the National Institute for Health and Clinical Excellence states in its latest draft guidance.The draft guidance takes into consideration the proposed patient access scheme,negotiated between GlaxoSmithKHne and the Department of Health(PJ,9 August 2008.p152),under which GSK would pay for the first 12 weeks of treatment with the NHS bearing the cost thereafter.